FYERS
Home
/
Stocks
/
Profit Loss
/
Windlas Biotech Profit & Loss

Windlas Biotech Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020
₹248 Cr₹238 Cr₹233 Cr₹222 Cr₹210 Cr₹203 Cr₹195 Cr₹187 Cr₹175 Cr₹171 Cr₹162 Cr₹153 Cr₹145 Cr₹141 Cr₹120 Cr₹133 Cr₹120 Cr₹122 Cr₹118 Cr₹115 Cr₹111 Cr₹107 Cr₹117 Cr₹101 Cr₹102 Cr
₹5 Cr₹4 Cr₹5 Cr₹4 Cr₹5 Cr₹5 Cr₹4 Cr₹5 Cr₹4 Cr₹4 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹1 Cr₹69 L₹79 L₹99 L₹62 L₹69 L
₹253 Cr₹243 Cr₹238 Cr₹226 Cr₹215 Cr₹208 Cr₹199 Cr₹192 Cr₹179 Cr₹176 Cr₹165 Cr₹156 Cr₹147 Cr₹143 Cr₹122 Cr₹135 Cr₹123 Cr₹125 Cr₹119 Cr₹116 Cr₹112 Cr₹108 Cr₹118 Cr₹102 Cr₹103 Cr
₹229 Cr₹221 Cr₹216 Cr₹201 Cr₹191 Cr₹185 Cr₹177 Cr₹170 Cr₹160 Cr₹153 Cr₹145 Cr₹137 Cr₹131 Cr₹128 Cr₹109 Cr₹120 Cr₹109 Cr₹111 Cr₹108 Cr₹105 Cr₹102 Cr₹99 Cr₹103 Cr₹92 Cr₹91 Cr
₹32 Cr₹30 Cr₹29 Cr₹32 Cr₹32 Cr₹30 Cr₹28 Cr₹28 Cr₹25 Cr₹26 Cr₹24 Cr₹22 Cr₹20 Cr₹19 Cr₹16 Cr₹19 Cr₹17 Cr₹17 Cr₹15 Cr₹14 Cr₹13 Cr₹12 Cr₹18 Cr₹13 Cr₹15 Cr
₹2 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹49 L₹28 L₹31 L₹29 L₹24 L₹16 L₹16 L₹12 L₹35 L₹29 L₹21 L₹44 L₹48 L₹32 L₹41 L₹30 L₹25 L
₹23 Cr₹20 Cr₹20 Cr₹24 Cr₹23 Cr₹21 Cr₹20 Cr₹20 Cr₹18 Cr₹23 Cr₹20 Cr₹18 Cr₹16 Cr₹15 Cr₹13 Cr₹16 Cr₹14 Cr₹14 Cr₹11 Cr₹11 Cr₹10 Cr₹8 Cr₹15 Cr₹9 Cr-₹21 Cr
₹18 Cr₹16 Cr₹15 Cr₹18 Cr₹18 Cr₹16 Cr₹15 Cr₹16 Cr₹13 Cr₹17 Cr₹15 Cr₹14 Cr₹12 Cr₹11 Cr₹9 Cr₹12 Cr₹10 Cr₹15 Cr₹8 Cr₹8 Cr₹7 Cr₹6 Cr₹12 Cr₹9 Cr-₹23 Cr

Share Price Live Stats

Open (₹)1,129.90
Volume (₹)1.48 L
High (₹)1,152.40
Upper Circuit1,352.50
Low (₹)1,125.50
Lower Circuit901.70
Prev Close1,127.10
52W High (₹)1,152.40
Price1,131.30
52W Low (₹)697.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)2329.42 Cr
Div. Yield (%)0.56
PE Ratio35.05
Debt to Equity0.05
Price to Book2.77
Book Value265.88
EPS (TTM)32.20
Face Value5.00
ROE (%)12.52

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
WINDLASNSE
LTP
1W Low
1W High
Market cap (₹)
1900-20 (-1.04%)
1896.80
1984.80
4,56,833Cr
9150-89 (-0.96%)
9087
9467
2,45,426Cr
4829.5-220.5 (-4.37%)
4827
5066
1,87,320Cr
1129.2-61.8 (-5.19%)
1125.10
1187
1,13,217Cr
1379.3-44.2 (-3.11%)
1376
1426.10
1,12,212Cr
1846.3-92.2 (-4.76%)
1811.70
1949
1,01,155Cr
2111-60.5 (-2.79%)
2110.30
2192
97,626Cr
2335.3-47.6 (-2.00%)
2334
2419.20
96,859Cr
1157.7-20.3 (-1.72%)
1154.40
1179.90
96,406Cr
1653.3+8 (0.49%)
1622.60
1717
93,614Cr
1131.3+132.75 (13.29%)
986.10
1152.40
2,329Cr

Key Highlights of Windlas Biotech Ltd’s P&L

In 2026-03-31, Windlas Biotech Ltd reported total revenue of ₹921.89Cr, compared with ₹777.9Cr in 2025-03-31, reflecting Windlas Biotech Ltd turnover.

Depreciation was ₹30.74Cr and finance costs were ₹4.83Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹86.98Cr in 2026-03-31 as compared to ₹79.76Cr in 2025-03-31.

Net Profit (PAT) was ₹66.46Cr in 2026-03-31 compared with ₹60.99Cr in 2025-03-31.

Earnings per share (EPS) were ₹31.49 in 2026-03-31, compared with ₹29.10 in 2025-03-31.